The total number of records retrieved from this search are 4. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_741	Virus nameAdenovirus	Virus strainAdAFPp-E1A-122	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationThe viral insertion mutant with miR-122 target sequence into AdAFPp-E1A for negatively regulating E1A gene expression	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2 with mimics	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to HL-7702 cell line	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result80% cancer cell viability on day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327
IDOV_743	Virus nameAdenovirus	Virus strainAdAFPp-E1A-122	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationThe viral insertion mutant with miR-122 target sequence into AdAFPp-E1A for negatively regulating E1A gene expression	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2 with mimics	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to HL-7702 cell line	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result65% cancer cell viability on day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327
IDOV_745	Virus nameAdenovirus	Virus strainAdAFPp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationThe viral mutant with E1A gene driven by AFP promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2 with mimics	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to HL-7702 cell line	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result61% cancer cell viability on day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327
IDOV_747	Virus nameAdenovirus	Virus strainAdAFPp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationThe viral mutant with E1A gene driven by AFP promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2 with mimics	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to HL-7702 cell line	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result46% cancer cell viability on day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327